The largest supplier of first-line anti-TB medicines globally.
Our journey began with a mission to address the growing burden of tuberculosis. Our founder, Dr. Desh Bandhu Gupta, established the company with a vision of developing high-quality, affordable medication to combat TB and improve global health outcomes.
Legacy Behind Our Fight Against TB
Our commitment to anti-TB treatment is rooted in the personal journey of our founder, DBG. As a young boy growing up in Rajasthan, India, he witnessed the devastating impact of TB, when a close childhood friend succumbed to the disease.
At a time when effective medicines existed but remained inaccessible to many in the country, this loss left a lasting impression on him. Years later, when he founded Lupin with a vision to make high-quality medication affordable and accessible, TB became one of our earliest and most important focus areas.
What began as a great personal resolve has since evolved into a global mission, expanding access to life-saving TB treatment for patients globally.
Today, we are the world’s leading suppliers of anti-tuberculosis medicines, with strong manufacturing capabilities and deep expertise in TB drug development.
The largest supplier of first-line anti-TB medicines globally.
A leading supplier to international procurement agencies such as the Global Drug Facility.
A trusted supply partner to governments in high TB-burden countries across Africa and Asia.
We have advanced fermentation technology and strong API manufacturing capabilities.
We operate with fully integrated production systems and facilities compliant with US FDA, UK MHRA, and WHO GMP standards.
Our anti-TB portfolio supports treatment, prevention, and management of tuberculosis across multiple disease stages.
Standard first-line treatment regimens used globally for tuberculosis management.
Advanced therapies designed to treat tuberculosis resistant to conventional drugs.
Preventive treatment for individuals at high risk of developing active TB.
Child-friendly treatment formulations, designed to improve treatment adherence and outcomes.
Disclaimer: The content on this website/webpage relates to a specific therapy/therapeutic area and is intended solely for informational and educational purposes for healthcare professionals and patients across India and other global locations, is not intended to substitute professional medical advice, diagnosis, or treatment. Advice from a physician or other qualified healthcare professional must be sought for any queries regarding a medical condition or treatment. Information on this website/webpage should not be solely used or relied upon in the absence of or delay in receiving professional medical advice. While Lupin makes reasonable efforts to ensure that the information is accurate and up to date, it makes no representations or warranties regarding its completeness or accuracy and accepts no liability for reliance on such information. The information on this website/webpage is not a substitute for prescribing information or patient information leaflets accompanying any medicinal product. The information on this website/webpage is subject to change without notice and may not reflect the most current medical, scientific, or regulatory developments. All content on this website/webpage is the intellectual property of Lupin and shall not be reproduced, modified, distributed, or used for any commercial purpose without the prior written consent of Lupin.
Our anti-TB portfolio is supported by strong API manufacturing capabilities and expertise in fermentation technologies essential for TB drug production.
A combination medicine used in the treatment of tuberculosis. It prevents the growth of microorganisms that cause infection.
Combination therapy is commonly used as a part of standard TB treatment. It prevents the growth of microorganisms that cause infection.
A portfolio of fixed-dose anti-TB medicines used in TB management programs.
We continue to expand access to affordable TB treatment through innovation and global partnerships.
Tuberculosis remains one of the world’s most pressing public health challenges, and addressing this disease requires ongoing innovation, collaboration, and equitable access to life-saving medicines.
For Lupin, the fight against TB is deeply rooted in our history and continues to guide our mission today. Through scientific innovation, global partnerships, and affordable access to medicines, we remain committed to advancing the goal of a TB-free world.
